The Center for Biosimilars® recaps the top stories for the week of October 7, 2019.
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 7, 2019.
Number 5: A new study reports that, for children who switch to biosimilars, factors like device type, citrates, and even color can be primary concerns.
Number 4: The Institute for Clinical and Economic Review says that brand-name adalimumab, rituximab, and pegfilgrastim, all of which have approved biosimilars, have seen substantial increases to price that have not been supported by new clinical data.
Number 3: Nevada’s Department of Health and Human Services sent letters to drug firms that did not provide required information about their costs, and it issued $17.4 million in penalties for noncompliance.
Number 2: The FDA has approved Pfenex’s follow-on teriparatide, referencing Forteo, for the treatment of osteoporosis.
Number 1: The FDA has issued a complete response letter for Tanvex’s proposed filgrastim biosimilar.
Finally, last week, our e-newsletter asked whether you think that the United States should allow external reference pricing to help reduce drug costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.